Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
Part of paid clinical trials in Columbus, Ohio.
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Study ID
- NCT02716246
- Phase
- PHASE2/PHASE3
- Status
- Recruiting
Conditions
- MPS IIIA
- Mucopolysaccharidosis III
- Sanfilippo A
- Sanfilippo Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- UX111 — BIOLOGICALSelf-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
- Prophylactic Immunomodulatory (IM) Therapy — DRUG
- Optimized Prophylactic IM Therapy — DRUG
- Adjuvant IM Therapy — DRUGThe Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.
Study Details
The main objective of this study is to evaluate the efficacy and safety of UX111 for the treatment of MPS IIIA.
Key Dates
- Start date
- Apr 25, 2016
- Status verified
- Jun 2026
- Primary completion
- Mar 31, 2029
- Completion
- Mar 31, 2029
Study Design
- Enrollment
- 36 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort 1 Low DoseDose of 0.5 X 10\^13 vg/kg
- Experimental: Cohort 2 Mid DoseDose of 1 X 10\^13 vg/kg
- Experimental: Cohort 3 High DoseDose of 3 X 10\^13 vg/kg
- Experimental: Cohort 4 High Dose (Spain Only)Dose of 3 X 10\^13 vg/kg
Primary Outcome Measure
Cerebrospinal Fluid (CSF) Heparan Sulfate (HS) (Disaccharide) Exposure [ Time Frame: Up to Month 24 Visit ]
Central Contacts
- Patients Contact: Trial Recruitment1-888-756-8657
- HCPs Contact: Medical Information1-888-756-8657
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Nationwide Children's Hospital | Columbus | Ohio | 43205 | - |
| Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania | 15224 | - |
Find similar trials in Columbus, OH
Related Studies
- Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIAPHASE3 · Enrolling By Invitation · Ultragenyx Pharmaceutical Inc · Columbus, Ohio
- Study of Cannabidiol in Sanfilippo SyndromePHASE2/PHASE3 · Recruiting · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · Torrance, California
- An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS IIIPHASE2/PHASE3 · Recruiting · Ozlem Goker-Alpan · Fairfax, Virginia